Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects

Recent advances in the management of prostate cancer have shown considerable development with time and many novel therapeutic agents have been approved over the past years. For patients with metastatic castration-resistant prostate cancer (mCRPC), initially docetaxel was the standard chemotherapy bu...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacology & pharmacotherapeutics 2013-10, Vol.4 (4), p.230-237
Main Author: Abidi, Afroz
Format: Article
Language:English
Subjects:
Androgens
Cancer
Cancer therapies
Care and treatment
Drug dosages
Drug therapy
Health aspects
Marketing
Mini Review
Molecular weight
Mortality
Pharmacology
Population
Prostate cancer
Quality of life
Tumors
Vaccines
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c588t-83545f9fb4a37db155dc93cada3ad0e3e379c7b13db86bcf436005e83e7a53fd3
cites
container_end_page 237
container_issue 4
container_start_page 230
container_title Journal of pharmacology & pharmacotherapeutics
container_volume 4
creator Abidi, Afroz
description Recent advances in the management of prostate cancer have shown considerable development with time and many novel therapeutic agents have been approved over the past years. For patients with metastatic castration-resistant prostate cancer (mCRPC), initially docetaxel was the standard chemotherapy but once they became refractory to docetaxel, no treatment improved survival. This scenario changed in June 2010 when the US Food and Drug Administration (FDA) approved Cabazitaxel as a new therapeutic option for patients with mCRPC resistant to docetaxel. Cabazitaxel, being a novel tubulin-binding taxane with poor affinity for P-glycoprotein, decreases the chances of resistance. It has shown antitumor activity in preclinical, phase I, II and III clinical studies in docetaxel-resistant tumors. This article summarises the background, pharmacodynamic, kinetics and clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Future development and rational use of this drug in other tumors is under therapeutic investigation.
doi_str_mv 10.4103/0976-500X.119704
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3825997</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A346337888</galeid><sourcerecordid>A346337888</sourcerecordid><originalsourceid>FETCH-LOGICAL-c588t-83545f9fb4a37db155dc93cada3ad0e3e379c7b13db86bcf436005e83e7a53fd3</originalsourceid><addsrcrecordid>eNptkt9vFCEQxzdGY5vad5_MJibGlz3hgFvwweRy8VfSxBdN-kZYdujRsLAC27T-9bJ359kzwgPDzGcGGL5V9RKjBcWIvEOiXTUMoesFxqJF9El1fnBh_vRoo-uz6jKlW1QGERRR8bw6W9JloQQ_rx42qlO_bFb34N7X69qHO3B12SoPtQmxHiCrlFW2utbFiMUKvomQbPH6XI8xzGEoUa8hNnqKEYrfDqOzekenWvm-NlOeIuz4EXROL6pnRrkEl4f1ovrx6eP3zZfm6tvnr5v1VaMZ57nhhFFmhOmoIm3fYcZ6LYhWvSKqR0CAtEK3HSZ9x1edNpSsEGLACbSKEdOTi-rDvu44dQP0ulwuKifHaAcVH2RQVp5GvN3Km3AnCV8yIdpS4O2hQAw_J0hZDjZpcK60KExJYkYRRhzjZUFf_4Pehin68jyJKaWMEt7iv9SNciCtN6Gcq-eick3oipCWc16oxX-oMnsYrA4ejC3-k4Q3jxK2oFzepuCm3RecgmgP6vIXKYI5NgMjOUtLztqRs3bkXlol5dXjJh4T_giJ_Aackcre</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1444543871</pqid></control><display><type>article</type><title>Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Sage Journals GOLD Open Access 2024</source><creator>Abidi, Afroz</creator><creatorcontrib>Abidi, Afroz</creatorcontrib><description>Recent advances in the management of prostate cancer have shown considerable development with time and many novel therapeutic agents have been approved over the past years. For patients with metastatic castration-resistant prostate cancer (mCRPC), initially docetaxel was the standard chemotherapy but once they became refractory to docetaxel, no treatment improved survival. This scenario changed in June 2010 when the US Food and Drug Administration (FDA) approved Cabazitaxel as a new therapeutic option for patients with mCRPC resistant to docetaxel. Cabazitaxel, being a novel tubulin-binding taxane with poor affinity for P-glycoprotein, decreases the chances of resistance. It has shown antitumor activity in preclinical, phase I, II and III clinical studies in docetaxel-resistant tumors. This article summarises the background, pharmacodynamic, kinetics and clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Future development and rational use of this drug in other tumors is under therapeutic investigation.</description><identifier>ISSN: 0976-500X</identifier><identifier>EISSN: 0976-5018</identifier><identifier>DOI: 10.4103/0976-500X.119704</identifier><identifier>PMID: 24250198</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Androgens ; Cancer ; Cancer therapies ; Care and treatment ; Drug dosages ; Drug therapy ; Health aspects ; Marketing ; Mini Review ; Molecular weight ; Mortality ; Pharmacology ; Population ; Prostate cancer ; Quality of life ; Tumors ; Vaccines</subject><ispartof>Journal of pharmacology &amp; pharmacotherapeutics, 2013-10, Vol.4 (4), p.230-237</ispartof><rights>COPYRIGHT 2013 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications &amp; Media Pvt Ltd Oct-Dec 2013</rights><rights>Copyright: © Journal of Pharmacology and Pharmacotherapeutics 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c588t-83545f9fb4a37db155dc93cada3ad0e3e379c7b13db86bcf436005e83e7a53fd3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825997/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1444543871?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24250198$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abidi, Afroz</creatorcontrib><title>Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects</title><title>Journal of pharmacology &amp; pharmacotherapeutics</title><addtitle>J Pharmacol Pharmacother</addtitle><description>Recent advances in the management of prostate cancer have shown considerable development with time and many novel therapeutic agents have been approved over the past years. For patients with metastatic castration-resistant prostate cancer (mCRPC), initially docetaxel was the standard chemotherapy but once they became refractory to docetaxel, no treatment improved survival. This scenario changed in June 2010 when the US Food and Drug Administration (FDA) approved Cabazitaxel as a new therapeutic option for patients with mCRPC resistant to docetaxel. Cabazitaxel, being a novel tubulin-binding taxane with poor affinity for P-glycoprotein, decreases the chances of resistance. It has shown antitumor activity in preclinical, phase I, II and III clinical studies in docetaxel-resistant tumors. This article summarises the background, pharmacodynamic, kinetics and clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Future development and rational use of this drug in other tumors is under therapeutic investigation.</description><subject>Androgens</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Health aspects</subject><subject>Marketing</subject><subject>Mini Review</subject><subject>Molecular weight</subject><subject>Mortality</subject><subject>Pharmacology</subject><subject>Population</subject><subject>Prostate cancer</subject><subject>Quality of life</subject><subject>Tumors</subject><subject>Vaccines</subject><issn>0976-500X</issn><issn>0976-5018</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkt9vFCEQxzdGY5vad5_MJibGlz3hgFvwweRy8VfSxBdN-kZYdujRsLAC27T-9bJ359kzwgPDzGcGGL5V9RKjBcWIvEOiXTUMoesFxqJF9El1fnBh_vRoo-uz6jKlW1QGERRR8bw6W9JloQQ_rx42qlO_bFb34N7X69qHO3B12SoPtQmxHiCrlFW2utbFiMUKvomQbPH6XI8xzGEoUa8hNnqKEYrfDqOzekenWvm-NlOeIuz4EXROL6pnRrkEl4f1ovrx6eP3zZfm6tvnr5v1VaMZ57nhhFFmhOmoIm3fYcZ6LYhWvSKqR0CAtEK3HSZ9x1edNpSsEGLACbSKEdOTi-rDvu44dQP0ulwuKifHaAcVH2RQVp5GvN3Km3AnCV8yIdpS4O2hQAw_J0hZDjZpcK60KExJYkYRRhzjZUFf_4Pehin68jyJKaWMEt7iv9SNciCtN6Gcq-eick3oipCWc16oxX-oMnsYrA4ejC3-k4Q3jxK2oFzepuCm3RecgmgP6vIXKYI5NgMjOUtLztqRs3bkXlol5dXjJh4T_giJ_Aackcre</recordid><startdate>20131001</startdate><enddate>20131001</enddate><creator>Abidi, Afroz</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Sage Publications Ltd</general><general>Medknow Publications &amp; Media Pvt Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20131001</creationdate><title>Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects</title><author>Abidi, Afroz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c588t-83545f9fb4a37db155dc93cada3ad0e3e379c7b13db86bcf436005e83e7a53fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Androgens</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Health aspects</topic><topic>Marketing</topic><topic>Mini Review</topic><topic>Molecular weight</topic><topic>Mortality</topic><topic>Pharmacology</topic><topic>Population</topic><topic>Prostate cancer</topic><topic>Quality of life</topic><topic>Tumors</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abidi, Afroz</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Research Library China</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of pharmacology &amp; pharmacotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abidi, Afroz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects</atitle><jtitle>Journal of pharmacology &amp; pharmacotherapeutics</jtitle><addtitle>J Pharmacol Pharmacother</addtitle><date>2013-10-01</date><risdate>2013</risdate><volume>4</volume><issue>4</issue><spage>230</spage><epage>237</epage><pages>230-237</pages><issn>0976-500X</issn><eissn>0976-5018</eissn><abstract>Recent advances in the management of prostate cancer have shown considerable development with time and many novel therapeutic agents have been approved over the past years. For patients with metastatic castration-resistant prostate cancer (mCRPC), initially docetaxel was the standard chemotherapy but once they became refractory to docetaxel, no treatment improved survival. This scenario changed in June 2010 when the US Food and Drug Administration (FDA) approved Cabazitaxel as a new therapeutic option for patients with mCRPC resistant to docetaxel. Cabazitaxel, being a novel tubulin-binding taxane with poor affinity for P-glycoprotein, decreases the chances of resistance. It has shown antitumor activity in preclinical, phase I, II and III clinical studies in docetaxel-resistant tumors. This article summarises the background, pharmacodynamic, kinetics and clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Future development and rational use of this drug in other tumors is under therapeutic investigation.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>24250198</pmid><doi>10.4103/0976-500X.119704</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0976-500X
ispartof Journal of pharmacology & pharmacotherapeutics, 2013-10, Vol.4 (4), p.230-237
issn 0976-500X
0976-5018
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3825997
source Open Access: PubMed Central; Publicly Available Content Database (Proquest) (PQ_SDU_P3); Sage Journals GOLD Open Access 2024
subjects Androgens
Cancer
Cancer therapies
Care and treatment
Drug dosages
Drug therapy
Health aspects
Marketing
Mini Review
Molecular weight
Mortality
Pharmacology
Population
Prostate cancer
Quality of life
Tumors
Vaccines
title Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A42%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cabazitaxel:%20A%20novel%20taxane%20for%20metastatic%20castration-resistant%20prostate%20cancer-current%20implications%20and%20future%20prospects&rft.jtitle=Journal%20of%20pharmacology%20&%20pharmacotherapeutics&rft.au=Abidi,%20Afroz&rft.date=2013-10-01&rft.volume=4&rft.issue=4&rft.spage=230&rft.epage=237&rft.pages=230-237&rft.issn=0976-500X&rft.eissn=0976-5018&rft_id=info:doi/10.4103/0976-500X.119704&rft_dat=%3Cgale_pubme%3EA346337888%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c588t-83545f9fb4a37db155dc93cada3ad0e3e379c7b13db86bcf436005e83e7a53fd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1444543871&rft_id=info:pmid/24250198&rft_galeid=A346337888&rfr_iscdi=true